[
  {
    "ts": null,
    "headline": "These 3 Stocks Are Healthcare Leaders. Bullish Charts Show It.",
    "summary": "Several non-biotech healthcare stocks are starting to show real momentum, breaking out of bases and asserting themselves as leaders in the sector.  With improving volume patterns, accelerating relative strength, and clean technical setups, this group of medical technology, services, and equipment stocks is quickly becoming one of the strongest pockets in the market.  As buyers rotate toward areas showing sustained upside follow-through, these healthcare names look poised to extend their momentum and deliver standout performance in the weeks ahead.",
    "url": "https://finnhub.io/api/news?id=2717af27688e4e76f1d5e55d3072bb6ad791b313d66d3edfb6f298ba48f4a8bf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765298820,
      "headline": "These 3 Stocks Are Healthcare Leaders. Bullish Charts Show It.",
      "id": 137742707,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Several non-biotech healthcare stocks are starting to show real momentum, breaking out of bases and asserting themselves as leaders in the sector.  With improving volume patterns, accelerating relative strength, and clean technical setups, this group of medical technology, services, and equipment stocks is quickly becoming one of the strongest pockets in the market.  As buyers rotate toward areas showing sustained upside follow-through, these healthcare names look poised to extend their momentum and deliver standout performance in the weeks ahead.",
      "url": "https://finnhub.io/api/news?id=2717af27688e4e76f1d5e55d3072bb6ad791b313d66d3edfb6f298ba48f4a8bf"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why You Should Retain OPKO Health Stock in Your Portfolio Now",
    "summary": "OPK leans on RAYALDEE momentum and strategic partnerships as pipeline trials advance, though reliance on its lone U.S. drug adds risk.",
    "url": "https://finnhub.io/api/news?id=320b0ceea2ef3a3fdb7981b14d1524c6cfcffec8a170b014ea715d033226ec2c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765283280,
      "headline": "Here's Why You Should Retain OPKO Health Stock in Your Portfolio Now",
      "id": 137740290,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "OPK leans on RAYALDEE momentum and strategic partnerships as pipeline trials advance, though reliance on its lone U.S. drug adds risk.",
      "url": "https://finnhub.io/api/news?id=320b0ceea2ef3a3fdb7981b14d1524c6cfcffec8a170b014ea715d033226ec2c"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific (BSX): Evaluating Valuation After Fresh Evidence of Sustained Growth in Minimally Invasive Devices",
    "summary": "Boston Scientific (BSX) is back on investors radar after fresh data underscored how its minimally invasive devices are translating into steady double digit growth in both revenue and earnings. See our latest analysis for Boston Scientific. Despite a choppy stretch, with the latest 1 day share price return at minus 3.77 percent and the 90 day share price return at minus 13.18 percent, Boston Scientific still posts a 1 year total shareholder return of 5.77 percent and a 3 year total shareholder...",
    "url": "https://finnhub.io/api/news?id=21e47ae49269a4b5766cffd8b189cce136f7098925bd987c2e38563cf573f723",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765271342,
      "headline": "Boston Scientific (BSX): Evaluating Valuation After Fresh Evidence of Sustained Growth in Minimally Invasive Devices",
      "id": 137740291,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Boston Scientific (BSX) is back on investors radar after fresh data underscored how its minimally invasive devices are translating into steady double digit growth in both revenue and earnings. See our latest analysis for Boston Scientific. Despite a choppy stretch, with the latest 1 day share price return at minus 3.77 percent and the 90 day share price return at minus 13.18 percent, Boston Scientific still posts a 1 year total shareholder return of 5.77 percent and a 3 year total shareholder...",
      "url": "https://finnhub.io/api/news?id=21e47ae49269a4b5766cffd8b189cce136f7098925bd987c2e38563cf573f723"
    }
  },
  {
    "ts": null,
    "headline": "Is Boston Scientific’s (BSX) Aggressive R&D Push Quietly Redefining Its Long‑Term Growth Story?",
    "summary": "In recent commentary, Boston Scientific highlighted expectations for sustained 8–10% annual revenue growth, margin expansion, and double-digit earnings growth powered by its electrophysiology, structural heart, and minimally invasive portfolios, including strong momentum in its FARAPULSE pulsed-field ablation platform and WATCHMAN left atrial appendage closure device. An interesting aspect of this update is the company's commitment to reinvesting 9–10% of revenue into R&D, underpinning a...",
    "url": "https://finnhub.io/api/news?id=1fc0997f17365b7256e24254c3fa8e98a0686fdc178a0b4f198399bca5a09130",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765267754,
      "headline": "Is Boston Scientific’s (BSX) Aggressive R&D Push Quietly Redefining Its Long‑Term Growth Story?",
      "id": 137740292,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "In recent commentary, Boston Scientific highlighted expectations for sustained 8–10% annual revenue growth, margin expansion, and double-digit earnings growth powered by its electrophysiology, structural heart, and minimally invasive portfolios, including strong momentum in its FARAPULSE pulsed-field ablation platform and WATCHMAN left atrial appendage closure device. An interesting aspect of this update is the company's commitment to reinvesting 9–10% of revenue into R&D, underpinning a...",
      "url": "https://finnhub.io/api/news?id=1fc0997f17365b7256e24254c3fa8e98a0686fdc178a0b4f198399bca5a09130"
    }
  }
]